{"analyses":[{"ciLowerLimit":"0.54","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.89","estimateComment":"Hazard Ratio (HR) was calculated from Cox proportional hazards model and Efron method was used in handling ties and computed using stratification factors at randomization.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0038","pValueComment":"Two-sided p-value calculated from stratified log-rank test.","paramType":"Cox Proportional Hazard","paramValue":"0.70","statisticalMethod":"Stratified log-rank test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.8","upperLimit":"14.9","value":"11.5"},{"groupId":"OG001","lowerLimit":"7.9","upperLimit":"10.7","value":"9.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"249"}],"units":"Participants"}],"description":"Overall survival is defined as the time from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with rCC/mCC were administered tisotumab vedotin 2.0 milligram per kilogram (mg/kg) as an intravenous (IV) infusion once every 3 weeks (Q3W).","id":"OG000","title":"Tisotumab Vedotin"},{"description":"Participants with rCC/mCC were treated with investigator's choice of chemotherapy which included either topotecan 1 or 1.25 milligram per meter square \\[mg/m\\^2\\] IV on Days 1 to 5, every 21 days or vinorelbine 30 mg/m\\^2 IV on Days 1 and 8, every 21 days or gemcitabine 1000 mg/m\\^2 IV on Days 1 and 8, every 21 days or irinotecan 100 or 125 mg/m\\^2 IV weekly for 28 days, every 42 days or pemetrexed 500 mg/m\\^2 on Day 1, every 21 days.","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"ITT analysis set included all randomized participants. Participants were included in the treatment group assigned at randomization regardless of any actual treatment received.","reportingStatus":"POSTED","timeFrame":"From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum up to 25 months)","title":"Overall Survival","type":"PRIMARY","unitOfMeasure":"Months"}